Therapeutic Value of Adeno Associated Virus as a Gene Therapy Vector for Parkinson's Disease - A Focused Review
- PMID: 27487991
- DOI: 10.2174/1566523216666160729113558
Therapeutic Value of Adeno Associated Virus as a Gene Therapy Vector for Parkinson's Disease - A Focused Review
Abstract
Although adeno-associated viral vectors have been studied for a long time, its importance as a viable gene therapy strategy has been thrusted into the limelight only in the recent years. Due to the admirable characteristics of these vectors, their potential has been thoughtfully utilized in the treatment of several neurodegenerative diseases. This mini-review focuses at recapitulating the therapeutic advances of adeno-associated viral vectors in the treatment of Parkinson's disease by studying the various animal model experiments and clinical trials conducted since the advent of adeno-associated viral vector - based gene therapy. Additionally, the chronological analysis of the studies in the review makes it easier to understand the challenges and foretell the future prospects in this field of therapeutics.
Keywords: AAV; Adeno associated virus; Gene therapy; Parkinson’s disease.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Similar articles
-
[Advances in the application of gene therapy for Parkinson's disease with adeno-associated virus].Yao Xue Xue Bao. 2014 May;49(5):576-81. Yao Xue Xue Bao. 2014. PMID: 25151724 Review. Chinese.
-
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.Lancet. 2007 Jun 23;369(9579):2097-105. doi: 10.1016/S0140-6736(07)60982-9. Lancet. 2007. PMID: 17586305 Clinical Trial.
-
Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.J Gene Med. 2014 Sep-Oct;16(9-10):300-8. doi: 10.1002/jgm.2779. J Gene Med. 2014. PMID: 25303717
-
Gene therapy of Parkinson's disease using adeno-associated virus (AAV) vectors.J Neural Transm Suppl. 2000;(58):181-91. doi: 10.1007/978-3-7091-6284-2_15. J Neural Transm Suppl. 2000. PMID: 11128607 Review.
-
Current development of adeno-associated viral vectors.Drug News Perspect. 2005 Jun;18(5):311-6. doi: 10.1358/dnp.2005.18.5.917326. Drug News Perspect. 2005. PMID: 16193103 Review.
Cited by
-
Gene therapy of yeast NDI1 on mitochondrial complex I dysfunction in rotenone-induced Parkinson's disease models in vitro and vivo.Mol Med. 2022 Mar 7;28(1):29. doi: 10.1186/s10020-022-00456-x. Mol Med. 2022. PMID: 35255803 Free PMC article.
-
Alpha-Synuclein and Microglia in Parkinson's Disease: From Pathogenesis to Therapeutic Prospects.J Clin Med. 2024 Nov 28;13(23):7243. doi: 10.3390/jcm13237243. J Clin Med. 2024. PMID: 39685702 Free PMC article. Review.
-
Gene and Cell Therapy for Muscular Dystrophies: Are We Getting There?Hum Gene Ther. 2018 Oct;29(10):1098-1105. doi: 10.1089/hum.2018.151. Hum Gene Ther. 2018. PMID: 30132372 Free PMC article. Review.
-
SIRT1 inactivation switches reactive astrocytes to an antiinflammatory phenotype in CNS autoimmunity.J Clin Invest. 2022 Nov 15;132(22):e151803. doi: 10.1172/JCI151803. J Clin Invest. 2022. PMID: 36136587 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical